Multi-Functional Anti-Inflammatory Drugs (MFAIDs) 

MFAIDs: A Novel Class of

PLA2-targeting Anti-Inflammatory Drugs-

Clinical Data in Contact Dermatitis Patients.

Yuval Cohen, PhD – President of Morria Biopharmaceuticals

Dr. Cohen received his PhD (summa cum lauda) from the Curie Institute in Paris in toxicology in 2002 and proceeded to co-found and head Morria Biopharmaceuticals (www.morria.com), a drug discovery and development company focused on the development of novel, non-steroidal, anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs).

These unique drugs target the PLA2 enzyme family, a sought-after pathway in the inflammation process upstream of current competitors.

Morria has two lead products in clinical development: MRX-4 (allergic rhinitis) and MRX-6 (contact dermatitis) as well as a number of promising pre-clinical programs. Yuval has authored numerous publications and patents and lives in New York city.

Please Note- we'll send directions in advance. GPS and Web maps will get you very lost.